13168 Federal Register / Vol. 62, No. 53 / Wednesday, March 19, 1997 / Notices

actually viewed by unauthorized

persons.

Case 9: Three attorneys prepared and

filed the public version of a brief that

contained bracketed but unredacted BPI

and served copies of the brief to parties

on the public service list and to other

non-authorized persons. The

Commission found that these attorneys

breached the APO and decided to issue

a warning letter to each of the attorneys.

(The Commission also found that two

other attorneys whose name appeared

on the brief did not breach the APO

because they did not assist in the

preparation of the public version of the

brief at issue). In making its decision,

the Commission noted that the breach

was inadvertent; the attorneys had not

previously breached an APO; they took

immediate action to mitigate the harm;

they immediately reported the potential

breach to the Commission; and it did

not appear that the BPI was actually

read by any unauthorized persons.

IV. Specific Investigations in Which No

Breach Was Found

As noted above, in three

investigations where the Commission

found a breach by one or more parties,

it also found that one or more parties

investigated did not breach the APO. In

addition, the Commission completed

one investigation in 1996 in which it

found that no breach by any party had

occurred. In that investigation, the

Commission reached its conclusion on

the basis of a finding that the BPI in

question, which was petitioner’s BPI,

had previously been publicly disclosed

by the petitioners.

V. Investigations of Breaches Other

Than in Antidumping or Countervailing

Duty Proceedings

In 1996, the Commission conducted

one investigation of an alleged breach of

an APO in a proceeding brought

pursuant to Section 201 of the Trade Act

of 1974. In that investigation, an APO

signatory sent the proprietary version of

a brief to a party on the public service

list that was not a party to the APO. The

Commission found that the signatory

breached the APO. In deciding to issue

only a warning letter, the Commission

pointed to the following factors: the

breach was inadvertent; the signatory

had not previously breached an APO;

the signatory took actions to mitigate

any harm by retrieving the unopened

envelope containing the brief; and thus

it did not appear that any unauthorized

persons viewed the BPI.

During 1996, the Commission did not

conduct any investigations of breaches

of APOs in proceedings filed under

Section 337 of the Tariff Act of 1930.

By order of the Commission.

Issued: March 13, 1997.

Donna R. Koehnke,

Secretary.

[FR Doc. 97–6904 Filed 3–18–97; 8:45 am]

BILLING CODE 7020–02–P

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: United

States International Trade Commission.

TIME AND DATE: March 28, 1997 at 11:00

a.m.

PLACE: Room 101, 500 E Street S.W.,

Washington, DC 20436.

STATUS: Open to the public.

MATTERS TO BE CONSIDERED:

1. Agenda for future meeting.

2. Minutes.

3. Ratification List.

4. Inv. No. 731–TA–760 (Preliminary)

(Needle Bearing Wire from Japan)—

briefing and vote.

5. Outstanding action jackets: none

In accordance with Commission

policy, subject matter listed above, not

disposed of at the scheduled meeting,

may be carried over to the agenda of the

following meeting.

Issued: March 13, 1997.

By order of the Commission:

Donna R. Koehnke,

Secretary.

[FR Doc. 97–6996 Filed 3–17–97; 9:57 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Office of Attorney Personnel

Management

Justice Management Division

Agency Information Collection

Activities: Proposed Collection;

Reinstatement, Without Change, of a

Previously Approved Collection for

Which Approval has Expired

ACTION: Application Booklets—Attorney

General’s Honor Program, Summer Law

Intern Program, Law Student Program.

Office of Management and Budget

(OMB) approval is sought for the

information collection listed below.

This proposed information collection

was previously published in the Federal

Register and allowed 60 days for public

comment.

The purpose of this notice is to allow

an additional 30 days for public

comments from the date listed at the top

of this page in the Federal Register.

This process is conducted in accordance

with 5 Code of Federal Regulation, Part

1320.10. Written comments and/or

suggestions regarding the item(s)

contained in this notice, especially

regarding the estimated public burden

and associated response time, should be

directed to the Office of Management

and Budget, Office of Information and

Regulatory Affairs, Attention:

Department of Justice Desk Officer,

Washington, DC 20503. Additionally,

comments may be submitted to OMB via

facsimile to 202–395–7285. Comments

may also be submitted to the

Department of Justice (DOJ), Justice

Management Division, Information

Management and Security Staff,

Attention: Department Clearance

Officer, Suite 850, 1001 G Street, NW,

Washington, DC, 20530. Additionally,

comments may be submitted to DOJ via

facsimile to 202–514–1534. Written

comments and suggestions from the

public and affected agencies should

address one or more of the following

points:

(1) Evaluate whether the proposed

collection of information is necessary

for the proper performance of the

functions of the agency/component,

including whether the information will

have practical utility;

(2) Evaluate the accuracy of the

agencies/components estimate of the

burden of the proposed collection of

information, including the validity of

the methodology and assumptions used;

(3) Enhance the quality, utility, and

clarity of the information to be

collected; and

(4) Minimize the burden of the

collection of information on those who

are to respond, including through the

use of appropriate automated,

electronic, mechanical, or other

technological collection techniques or

other forms of information technology,

e.g., permitting electronic submission of

responses.

Overview of this information

collection:

(1) Type of information collection:

Reinstatement, without change, of a

previously approved collection for

which approval has expired.

(2) The title of the form/collection:

Application Booklets—Attorney

General’s Honor Program, Summer Law

Intern Program, Law Student Program.

(3) The agency form number, if any,

and the applicable component of the

Department sponsoring the collection.

Form number: None. Office of Attorney

Personnel Management, Justice

Management Division, United States

Department of Justice.
Federal Register / Vol. 62, No. 53 / Wednesday, March 19, 1997 / Notices 13169

(4) Affected public who will be asked

or required to respond, as well as a brief

abstract. Primary: Individual or

households. Other: None. This data

collection is the only vehicle for the

Department of Justice (DOJ) to hire

graduating law students. This

application form is submitted

voluntarily, submitted only once a year

by students/judicial law clerks who will

be in this applicant pool only once; and

the information sought only relates to

the hiring criteria established as an

internal matter by DOJ personnel.

(5) An estimate of the total number of

respondents and the amount of time

estimate for an average respondent to

respond: 5,700 respondents at 1 hour

per response.

(6) An estimated of the total public

burden (in hours) associated with the

collection: 5,700 annual burden hours.

Public comment on this proposed

information collection is strongly

encouraged.

Dated: March 14, 1997.

Robert B. Briggs,

Department Clearance Officer, United States

Department of Justice.

[FR Doc. 97–6875 Filed 3–18–97; 8:45 am]

BILLING CODE 4410–24–M

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to § 1301.43(a) of Title 21 of

the Code of Federal Regulations (CFR),

this is notice that by application dated

August 8, 1996, and relevant written

statements of fact received January 8,

1997, B.I. Chemical, Inc., 2820 N.

Normandy Drive, Petersburg, Virginia

23805, made application to the Drug

Enforcement Administration (DEA) for

registration as a bulk manufacturer of

the basis classes of controlled

substances listed below:

Drug Schedule

Methadone (9250) ...................... II

Methadone-intermediate (9254) II

Levo-alphacetylmethadol (LAAM)

(9648).

II

The firm plans to manufacturer the

listed controlled substances in bulk for

distribution to its parent company for

formulation into finished

pharmaceuticals.

Any other such applicant and any

person who is presently registered with

DEA to manufacturer such substances

may file comments or objectives to the

issuance of the above application.

Any such comments or objections

may be addressed, in qunituplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than May 19,

1997.

Dated: February 21, 1997.

Gene R. Haislip,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 97–6920 Filed 3–18–97; 8:45 am]

BILLING CODE 4410–09–M

Importation of Controlled Substances;

Notice of Application

Pursuant to Section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this Section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under Section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with Section

1311.42 of Title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on May 6, 1996, Glaxo

Wellcome Inc., Attn: Jeffrey A. Weiss,

1011 North Arendell Avenue, P.O. Box

1217, Zebulon, North Carolina 27597–

2309, made application to the Drug

Enforcement Administration to be

registered as an importer of remifentanil

(9739), which did not become a basic

class of controlled substance in

Schedule II until November of 1996.

Therefore, this application was not

processed until remifentanil was

controlled and relevant statements of

fact dated February 12, 1997, were

received.

The remifentanil is being imported for

the production of Ultiva dosage forms

and for research and new product

development.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of this basic class of

controlled substance may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.54 in

such form as prescribed in 21 CFR

1316.47.

Any such comments, objections, or

requests for a hearing may be addressed

to the Acting Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, DC

20537, Attention: DEA Federal Register

Representative (CCR), and must be filed

no later than April 18, 1997.

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1311.42 (b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import basic classes of

any controlled substances in Schedule I

or II are and will continue to be required

to demonstrate to the Acting Deputy

Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1311.42 (a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: March 12, 1997.

Terrance W. Woodworth,

Acting Deputy Assistant Administrator, Office

of Diversion Control, Drug Enforcement

Administration.

[FR Doc. 97–6921 Filed 3–18–97; 8:45 am]

BILLING CODE 4410–09–M

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated October 28, 1996, and

published in the Federal Register on

November 27, 1996 (61 FR 60305),

Hoffmann-LaRoche, Inc., 340 Kingsland

Street, Nutley, New Jersey 07110, made

application by renewal to the Drug

Enforcement Administration (DEA) to

be registered as a bulk manufacturer of

levorphanol (9220), a basic class of

controlled substance listed in Schedule

II.

DEA has considered the factors in

Title 21, United States Code, Section

923(a) and determined that the

registration of Hoffmann-LaRoche, Inc.

to manufacture levorphanol is

consistent with the public interest at

this time. Therefore, pursuant to 21

U.S.C. 823 and 28 C.F.R. 0.100 and

0.104, the Deputy Assistant

Administrator, Office of Diversion

Control, hereby orders that the

application submitted by the above firm

for registration as a bulk manufacturer

of the basic class of controlled substance

listed above is granted.